Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients  by Bienvenu, Anne-Lise et al.
International Journal of Infectious Diseases 46 (2016) 11–17Pneumocystis pneumonia suspected cases in 604 non-HIV and
HIV patients
Anne-Lise Bienvenu a,b,1, Karim Traore b,1, Irina Plekhanova b, Mourad Bouchrik b,
Ce´cile Bossard a, Ste´phane Picot a,b,*
a Institut de Parasitologie et Mycologie Me´dicale, Hospices Civils de Lyon, Lyon, France
bUniv Lyon, Universite´ Claude Bernard Lyon 1, Institut de Chimie et Biochimie Mole´culaire et Supramole´culaire, UMR-5246 CNRS-INSA-CPE,
Malaria Research Unit, Lyon, France
A R T I C L E I N F O
Article history:
Received 11 January 2016
Received in revised form 16 March 2016
Accepted 18 March 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Pneumocystosis
Pneumocystis jiroveci
HIV
non-HIV
Diagnosis
Prophylaxis
Outcome
Consensus
A B S T R A C T
Background: Pneumocystis pneumonia (PCP) is one of the most devastating fungal diseases in patients
with impaired immunity. Effective antiviral therapies have reduced the burden of PCP among AIDS
patients, but an increase in the prevalence of this disease among persons receiving immunosuppressive
therapies has been reported.
Methods: We retrospectively reviewed HIV and non-HIV PCP patients diagnosed in our department
during a nine year period. Data were collected from the local database completed during the diagnosis
procedure. For each patient, demographic, clinical, radiological, biological and therapeutic data were
analyzed.
Results: A total of 21,274 bronchoalveolar samples were received from patients suspected of
pneumocystosis during the study period, leading to a discharge diagnosis of PCP for 604 patients
(143 HIV-positive and 461 HIV-negative). The ratio of non-HIV versus HIV patients presenting PCP
increased from 1.7 to 5.6 during the study period. The mortality rate at day 14 was 16%, occurring mostly
in non-HIV patients (20.6% compared to 1.4%, P < 0.0001), while non-HIV patients were less
symptomatic at diagnosis than AIDS patients.
Conclusions: This study presents one of the higher number of HIV and non-HIV patients presenting with
PCP in a single center. Pneumocystosis is now a crucial health challenge for patients receiving
immunosuppressive therapy, with a high mortality rate. This study highlights the need for international
guidelines for prophylaxis of PCP in non-HIV patients.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pneumocystis pneumocystosis (PCP) is a continuously evolving
disease challenging clinicians involved in the cascade of care of
patients as different as people with impaired immunity, recipients
of solid organs transplants or people with hematologicalAbbreviations: PCP, Pneumocystis pneumonia; P. jirovecii, Pneumocystis jiroveci;
HIV, Human immunodeﬁciency Virus; Rt-PCR, Real-Time Polymerase Chain
Reaction.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).malignancies. The microbe responsible for that disease, Pneumo-
cystis jirovecii (P. jiroveci), is still poorly known, while scientists
decided that it belongs deﬁnitively to the kingdom of fungi based
on DNA sequence homology. It is not deﬁnitively known if the
disease is acquired from the environment or from colonized/
infected patients when risk factors are arising, or if the disease in
adults is a reactivation of dormant forms contracted during
infancy, or if reactivation or de novo infection may both occur in
different patients.1 The exact role of inter-human transmission is
still a matter of debate.2,3 P. jiroveci is still not adapted to in vitro
culture despite years of collaborative work to achieve this major
goal for a better understanding of its biology and for improvement
of its diagnosis.4–7 The utmost importance of pneumocystosis was
perceived at the time of HIV epidemic in humans, and a decade ago
it was expected that HIV control will lead to pneumocystosisciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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extensively studied in HIV positive patients and the global trend
in most countries where statistics are available is a decrease of
these cases for patients who have access to combination
antiretroviral therapy.9 There is clear evidence from the early
2000’s that pneumocystosis is no longer restricted to HIV patients,
but is mostly diagnosed in non-HIV patients, leading to new
challenges for prophylaxis, diagnosis and treatment in a larger
susceptible population. The number of studies with non-HIV
patients is rapidly increasing.10–13 Systematic analyses of
published literature or studies conducted at country level using
national health systems have conﬁrmed this general trend.14
Epidemiological, clinical and therapeutic backgrounds of pneu-
mocystosis in non-HIV patients have changed and seem to be
more diverse. General outcome should be considered with caution
since the causes of death of these patients is often multifactorial.
Higher mortality rates are reported by authors in HIV negative
patient compared to HIV positive patients.15,16
One of the major issues for clinicians is to identify patients
susceptible to P. jiroveci infection at the earlier stage of the risk
period in order to promote the use of systematic prophylaxis,
which has proven to be highly effective for HIV patients. A recent
Cochrane study has shown that prophylaxis with trimethoprime-
sulfamethoxazole should be considered for at risk non-HIV
patients, with a number needed to treat to prevent PCP of
19 patients, given an event rate of 6%.15
In this context, it was of interest to analyze cases of non-HIV
pneumocystosis during a nine year period in a single center with
standardized methods of diagnosis. Thus, we conducted a
retrospective study in our institution from January 2005 to
December 2013 in order to describe clinical, diagnostic and
treatment characteristics of Pneumocystis pneumonia in HIV
negative and positive patients.
2. Methods
2.1. Study population and sampling
This study was conducted at the Lyon teaching hospital
(approximately 5000 bed-facility) where bone marrow and solid
organ transplantation activities are common, as well as surgery,
intensive care and infectious diseases including HIV patients.
During the period from January 1st, 2005 to December 31st, 2013,
21274 samples (swab, broncho-aspiration, broncho-alveolar la-
vage, lung biopsy) from patients suspected of pneumocystosis
were collected. After conﬁrmation of the biological diagnosis, all
information from patients including age, sex, risk factors,
symptoms, chest computed tomography scan, biological diagnosis
(microscopic examination and real-time PCR), treatment and
outcome at day 14 post-diagnosis, were prospectively collected
from patient medical records and laboratory database.
2.2. Diagnosis procedure
The same diagnosis procedure has been followed during the
study period. Suspicion of pneumocystosis was based on
epidemiological, clinical and radiological ﬁndings. Symptoms
considered to be common during PCP were: progressive dyspnea,
nonproductive cough, and low-grade fever. Radiological signs
considered to be associated with PCP were bilateral perihilar
interstitial inﬁltrates. Samples collected from these patients were
systematically submitted to microscopic examination (ME) after
conventional staining methods (Diff-Quick and Grocott-metha-
mine silver stain) by two experienced microscopists. Discrepancies
were resolved by consensus.Samples showing no trophic forms or cysts by microscopic
examination were tested using real-time PCR (RT-PCR) according to
the method developed locally.18,19 Brieﬂy, DNA was extracted using
a QIAamp DNA Mini Kit according to the manufacturer’s recom-
mendations. Positive and negative controls were tested simulta-
neously, and two different external quality controls were performed
twice a year. Positive threshold of the method was 35 cycles.
The diagnosis of pneumocystosis was considered as conﬁrmed if
ME and/or real-time PCR were positive, or if anti-pneumocystis
treatment has been prescribed to patients based on clinical
conviction. Patients considered as being affected by pneumocystosis
were speciﬁcally treated according to international guidelines.8,20
Systematic PCR conﬁrmation of the positive microscopic
diagnosis was not required since quality controls performed
regularly showed no false-positive results from microscopy.
2.3. Statistical analysis
Categorical variables were analyzed with Chi-square test or
with Fisher’s exact test, as appropriate. Continuous variables were
analysed by Student’s t test. Data were analyzed by SPSS for
Windows version 11 (Chicago, USA). Difference was considered
signiﬁcant if p-value was below 0.05 (risk at 5% and conﬁdence
interval at 95%).
3. Ethical considerations
This research involved anonymized records and datasets where
it is not possible to identify an individual from the information
provided. De-identiﬁcation and removing of protected health
information from clinical narratives were performed according to
the European Textbook on Ethics in research (http://ec.europa.eu/
research/swafs/pdf/pub_archive/textbook-on-ethics-report_en.
pdf). Data used in this study were collected for the routine
diagnosis and clinical management of patients in the Lyon teaching
hospital, and no additional intervention was made on patients for
research purposes. Therefore, ethical clearance was not needed for
that study.
4. Results
4.1. Patient characteristics
From January 2005 to December 2013, 21274 samples were
received from patients suspected of pneumocystosis. A total of
604 patients with a diagnosis of pneumocystosis recorded on
clinical narratives at discharge [143 HIV-positive (23.7%) and
461 HIV-negative (76.3%)] were included in this study (Figure 1).
The overall mortality rate was 16% (97/604), mostly in non-HIV
patients (95/97).
Fifty-four patients (8.9%) did not present symptoms usually
associated with pneumocystosis (fever, cough or dyspnea), while
biological tests were positives for Pneumocystis jroveci (2 by
microsopic examination, and 52 by RT-PCR). Most of them were
HIV negative, 76% received anti-pneumocystis treatment, and
22.2% died. These patients should have been classiﬁed as colonized
by Pneumocystis.
Among the 550 patients with symptoms commonly associated
with pneumocystosis, 62 (11.3%) showed no Xray/TDM signs
suggestive of pneumocystosis. Finally, 488 patients (24.8% HIV-
positive and 75.2% HIV-negative) presented conventional clinical
symptoms and radiological signs compatible with pneumocystosis
(Figure 2).
The median age of the patients was 59 years (ranging from
3 months to 88 years of old) and the sex ratio male/female was 2.02
(404/200) (Table 1). Only 6.6% (40/604, including 13 HIV positive
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Figure 1. Enrollment, classiﬁcation and outcome of patients suspected of Pneumocystosis.
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the diagnosis of pneumocystosis.
In HIV negative patients, hematological malignancies consti-
tuted the predominant risk factor for pneumocystosis (39%),
followed by cancer of different organs (26.9%). More than eighty
two per cent (82.4%) of patients were using immunosuppressive
therapy. Risk factors for pneumocystosis of HIV negative patients
are shown in Table 2.
From 2005 to 2013, the total annual number of pneumocystosis
cases has increased by 39.5%. During the same period, the rate of
pneumocystosis has increased signiﬁcantly from 63% to 85% in
non-HIV patients (p = 0.004) and decreased from 37% to 15% in
HIV-positive patients (Figure 3).
4.2. Radiological ﬁndings
Radiological ﬁndings were suggestive of pneumocystosis for
86.4% (522/604) of patients. There was no difference between HIV-
positive (124/143) and HIV-negative (398/461) patients (p > 0.1).
In the group of patients under prophylaxis, 77.5% (31/40) had a
suggestive radiology compared to 87% (491/564) of patients
without prophylaxis (p = 0.08).
4.3. Clinical manifestations
The most frequent symptom was dyspnea 398/604 (65.9%),
followed by fever 395/604 (65.4%) and cough 337/604 (55.4%).
Thirty two percent of the patients (n = 195) presented with these3 symptoms, 31% (n = 188) with 2 symptoms (70 with fever and
dyspnea, 64 with dyspnea and cough, 54 with fever and cough) and
27.6% (n = 167) with 1 symptom (76 with fever, 68 with dyspnea
and 23 with cough).
Non-HIV patients presented less frequently with cough
(p = 0.0003) and dyspnea (p < 0.00001) compared to HIV patients.
Fever was not a discriminant symptom between the two groups of
patient (p = 0.08).
Only 54 patients (8.9%) were asymptomatic and should have
been considered as colonization, but among them 61% (33/54)
showed radiological abnormalities and 75.9% (41/54) received
anti-pneumocystis treatment. Asymptomatic presentation of
pneumocystosis was signiﬁcantly (p = 0.009) more frequent in
non-HIV patients (10.6%) compared to HIV-positive patients
(3.4%),
4.4. Biological diagnosis
Biological diagnosis of pneumocystosis was performed on
samples from 604 patients, including 521 broncho-alveolar
lavages, 56 swabs, 26 broncho-aspirations and 1 lung biopsy.
ME was positive for 181/604 patients (29.9%) and the 423 samples
from patients with a negative ME were all PCR positive. Since both
methods were used for 80 patients, Real-time PCR tests were
positive for a total of 503 patients. The positivity rates of ME were
32.6% for broncho-alveolar lavages (170/521); 10.7% for swab
(6/56) and 19.2% for broncho-aspiration (5/26). It was signiﬁcantly
more frequent to observe a positive ME from HIV-positive patients
Figure 2. Detailed description of patient’s characteristics, including clinical, radiological and biological data. 604 patients with a ﬁnal diagnosis of Pneumocystis pneumonia
were included, retrospective analysis was performed to classiﬁed patients according to the presence or lack of clinical or radiological signs. Patients were ﬁnally separated in
groups according to the method used for the biological diagnosis, and the HIV status.
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(p < 0.001). No difference was observed in the positivity rate of ME
of broncho-pulmonary samples between patients presenting
radiological abnormalities suggestive of the diagnosis of pneu-
mocystosis (158/522; 30.3%) compared to those with normal chest
X-ray (23/82; 28.0%), (p > 0.1).
The ME positivity rates for patients presenting 3, 2 or
1 symptoms (fever, dyspnea, cough) (29.7% (58/195) for
3 symptoms, 33% (62/188) for 2 symptoms, 31.1% (52/167) forTable 1
Patient characteristics, on inclusion, classiﬁed by HIV status
Total HIV-negative HIV-positive P
n 604 461 143
Median age (years) 59 [<1 - 88] 59 [<1 - 88] 59 [<1 - 88] > 0.5
Sex ratio (M/F) 2.02 1.66 4.29 < 0.005
Prophylaxis before
diagnosis
40 (6.6%) 27 (5.8%) 13 (9%) > 0.5
Radiological ﬁndings 522 (86.4%) 398 (86.3%) 124 (86.7%) > 0.5
Dyspnea 398 (65.9%) 297 (64.4%) 101 (70.6%) 0.00001
Fever 395 (65.4%) 293 (63.5%) 102 (71.3%) 0.08
Cough 337 (55.4%) 238 (51.6%) 99 (69.2%) 0.0003
Other symptoms 54 (8.9%) 49 (10.6%) 5 (3.4%) 0.0091 symptom), were not different from asymptomatic patients
(16.6%, 9/54) (p > 0.05).
Prophylaxis did not decrease the positivity rate of ME: 13/40
(32.5%) patients under prophylaxis had a positive ME compared to
168/564 (29.7%) patients without prophylaxis (p > 0.1).
4.5. Treatment
Around 97% (560/604) of patients received anti-Pneumocystis
treatment. Sulfamethoxazole + Trimethoprime was the most
frequent treatment (93.6%, 524/560), followed by atovaquone
(5.1%, 29/560) and pentamidin (1.3%, 7/560). Anti-Pneumocystis
treatment was initiated more frequently (p < 0.02) in HIV-positive
patients (97.2%, 139/143) compared to non-HIV patients (91.3%,
421/461).
As expected, positive ME led more frequently to anti-
Pneumocystis treatment than negative ME (97.2% (176/181) versus
90.7% (384/423)), (p = 0.005).
Initiation of treatment was lower when patients presented no
symptoms (79.6% (43/54), p = 0.0004), compared to patients
presenting 1 symptom (91.0% (152/167), p = 0.0003), 2 symptoms
(94.1%; 177/188) or 3 symptoms (96.4%; 188/195). Among the
21 patients without symptoms and without imagery ﬁndings, 62%
(13/21) were treated for pneumocystosis.
Table 2
Risk factors for HIV negative patients (n = 461)
Hematologic malignancies 181 (39.3%)
Lymphoma 84
Leukemia 66
Myeloma 15
Hodgkin 13
Myelodysplasia 3
Cancer 124 (26.9%)
Autoimmune disorders 52 (11.3%)
Rheumatoid polyarthritis 20
Dermatomyositis 5
Lupus 5
Anemia 4
Rectocolitis 4
Wegener 3
Others 11
Transplantation 34 (7.4%)
Kidney 19
Heart or heart and lung 10
Liver 5
Immunosuppressive therapies 380 (82.4%)
Corticosteroids 153
Chemotherapy 120
Corticosteroids + Chemotherapy 84
Other therapies 23
Other risk factors 48 (10.4%)
Pulmonary ﬁbrosis 13
Cirrhosis 5
DICS 3
Miscalleous 13
No risk factor identiﬁed 14
- Other autoimmune disorders: Berger, Crohn, Horton and Gougerot’s diseases,
Arteritis, Sarcoidosis, Cryoglobulinemia.
- Other therapies: methotrexate, tacrolimus, mycophenolate and others.
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The overall cases mortality rate at day 14 was 16% (97/604),
mostly in non-HIV patients, comparable to a previous study.21
There was no signiﬁcant difference in death rate (p > 0.1) between
patients receiving a prophylaxis (3/40; 7.5%) or not (94/564; 16%).
Non-HIV patients had a higher mortality rate (20.6%; 95/461)
compared to HIV positive patients (1.4%, 2/143), (p < 0.00001).0
20
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Figure 3. Annual number of Pneumocystis pneumonia (bars). Percentage of HIV-
positive (dashed line) and non-HIV patients (black line) per year.Clinical symptoms and radiological signs were not associated
with a higher death rate (p > 0.1 and p = 0.09 respectively). For
asymptomatic patients without radiological abnormalities
(n = 21), 3 patients died, two of them with an anti-Pneumocystis
treatment. Among the deceased patients, 87.6% (85/97) have a
negative direct examination.
5. Discussion
In our institution, we showed that pneumocystosis rate is
increasing among non-HIV patients. In less than ten years, the ratio
of non-HIV versus HIV patients presenting pneumocystosis
dramatically increased from 1.7 to 5.6. Most of the non-HIV
patients (357/461; 77.4%) were receiving corticosteroids and/or
chemotherapy, and the most frequent underlying diseases were
hematological malignancies and cancer (305/461; 66.1%).
Surprisingly, in our study, anti-Pneumocystis treatment was less
frequent in non-HIV patients (91.3%) compared to HIV patients
(97.2%) (P < 0.02). However, the mortality rates at day 14 were
higher in non-HIV patients compared to HIV patients, as
previously reported.15,22–24 Many confounding factors need to
be taken into account to avoid a misinterpretation of mortality
rates in patients with severe comorbidities. At the time of
diagnosis, Pneumocystosis was less symptomatic in non-HIV
patients compared to HIV positive patients. The absence of
symptoms was described as an independent predictor of
mortality.25 Moreover, longer symptom duration was described
in HIV patients compared to non-HIV patients whose symptoms
could occur less than 3 days.26 Consequently, these results
suggested that it is better not to rule out the diagnosis of
pneumocystosis in case of limited clinical expression in non-HIV
patients and to initiate the treatment as early as possible for non-
HIV patients suspected of Pneumocystosis,27 while speciﬁc drugs
may have signiﬁcant adverse effects.
We demonstrated, as previously described, that in non-HIV
patients, real-time PCR was more frequently positive than
microscopic examination. This could be explained by fewer
organisms present in non-HIV patients28,29 and by the higher
sensitivity of real time PCR compared to direct examination.30,31
Conventional PCR is not recommended as a molecular diagnostic
method for Pneumocystis ampliﬁcation due to its lack of sensitivi-
ty32 and speciﬁcity33 compared to real-time PCR. Quantitative real-
time PCR was claimed to be more speciﬁc than real-time PCR
avoiding the detection of colonized patients.34,35 However, in light
of the recently published studies, a standardized quantitative
method and a discriminant cut-off between colonized and infected
patients are still lacking.36–38
Negative Real-time PCR is highly contributive to rule out
pneumocystosis diagnosis in non-HIV patients due to its high
negative predictive value, close to 100% and thus sufﬁcient to
reasonably discontinue an anti-Pneumocystis treatment.39
It is known that Pneumocystis colonization does exist and is
deﬁned, in contrast to Pneumocystis infection, by the detection of
Pneumocystis, mostly by PCR-based techniques, in a patient
without signs or symptoms of acute pneumonia.1 According to
authors, colonization is more common in non-HIV patients and
could be a warning value for Pneumocystis prophylaxis in
immunosuppressed patients, especially if an increase in immuno-
suppression is planned.40,41 In our study, 21 patients had no
symptoms typical of pneumocystosis and no compatible imagery
ﬁndings, but only 8 of them did not receive speciﬁc treatment.
6. Conclusion
In regard to these results, we observed that pneumocystosis
outcome is more unfavorable in non-HIV patients compared to HIV
A.-L. Bienvenu et al. / International Journal of Infectious Diseases 46 (2016) 11–1716patients, probably because symptoms are less frequent and
treatment is less common, maybe subsequent to the scarcity of
positive microscopic examination results. Real-time PCR is a useful
tool for the diagnosis of Pneumocystis pneumonia in non-HIV
patients. Hence, a positive Pneumocystis real-time PCR should be
taken into account even if the patient does not have symptoms, but
has a risk factor (cancer or hematological disorder) and/or receives
an immunosuppressive therapy (corticosteroids and/or chemo-
therapy). For the patients who do not present these risk factors, the
biological diagnosis using ME and real-time PCR may constitute
the key elements to rule out the diagnosis of pneumocystosis. This
study also raises another major question related to the lack of
consensus on pneumocystosis prophylaxis in non-HIV patients
more prone to suffer severe pneumocystosis. Except for patients
undergoing allogeneic bone marrow transplantation, solid organ
transplantation, acute lymphoblastic leukemia and collagen
vascular diseases, little data are available for the other at-risk
patients.17
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